Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.American CryoStem has filed its first jointly-owned patent application with its research partners at Rutgers University titled, ‘Nanoparticle-Mediated Synthetic Transcription Factor for Enhanced Gene Regulation and Cell Differentiation’.
Subscribe to our email newsletter
In May 2013, American CryoStem entered into a series of agreements with research scientists at Rutgers, The State University of New Jersey, including Dr KiBum Lee, Professor of Chemistry and Chemical Biology.
American CryoStem’s initial collaboration with Dr. Lee, focused on utilizing American CryoStem’s proprietary ATCELL (Adipose-Derived Stem Cells (ADSCs)) and patented, ACSelerate (animal serum free), GMP grade, cell culture and differentiation mediums to enhance Dr Lee’s multi-functional nanotechnology and biomaterial platforms (NanoScript) that are capable of directing adipose-derived stem cell differentiation.
The combined technologies create a regenerative medicine platform which can be used to treat a wide range of degenerative diseases and orthopedic injuries.
NanoScript is a platform technology, based on the combination of nanosized particles including gold and other unique FDA approved biomaterials, with a series of predetermined peptides and binding domains in specific ratios to create a synthetic transcription factor capable of differentiating hADSCs without introducing a virus or altering the cells DNA.
NanoScript technology is multi-functional and synergistic for use with the Company’s proprietary products to create any cell type including, but not limited to; muscle, cartilage, bone, adipocyte, neural and induced pluripotent cells (IPSCs) that are a genetic match for the donor.
The company believes that this technology, to induce differentiation without introducing a virus to the cell, provides the company an opportunity to create a series of cellular therapy applications to treat chronic disease and traumatic injury, while at the same time overcoming certain genetic hurdles associated with generic cellular therapies.
Dr Lee noted that the collaboration with American CryoStem has allowed it to complete its ADSC-NanoScript technology platform and to advance its research to produce the repeatable results necessary for clinical development and FDA submission.
"The ability to work with an FDA-registered laboratory with a unique and continuously expanding stem cell bank to ensure quality, uniformity and cellular purity is key to creating our master file for regulatory commercial product approval. The ATCELL offering has greatly accelerated our platform technology which will be described in a forthcoming white paper detailing our ADSC-NanoScript research findings," Dr Lee added.
The initial focus of the Rutgers-American CryoStem collaboration has been on the regeneration of muscle cells for the repair of muscle loss from systemic disease and physical trauma, both of which are large, under-satisfied, medical needs without a repeatable cellular therapy solution.
Further applications such as nerve repair for systemic disease and traumatic injuries, which markets the company believes are underserved, are in the initial stages of development.